secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001299130-24-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q4 rev $58.4M (+113% YoY) but GAAP gross margin drops to 16%; FY rev $200.5M
--------------------------------------------------------------------------------

- Q4 revenue $58.4M (+113% YoY); instrument revenue $35.1M vs $6.1M YoY.
- GAAP gross margin 16% (vs 19% YoY); $9.3M inventory reserve charges from faster Revio ramp.
- Net loss $82.0M ($0.31/share) vs $84.4M ($0.37) PY; non-GAAP loss $72.5M.
- Shipped 44 Revio systems; installed base 173; consumables revenue $18.9M (+13% YoY).
- FY2023 rev $200.5M (+56% YoY); net loss $306.7M vs $314.2M; cash $631.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913024000014/0001299130-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913024000014/pacb-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001299130-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer